Sp646

MECHANISMS FOR THE CHANGING EPIDEMIOLOGY OF COLORECTAL CANCER: A BASIC/TRANSLATIONAL PERSPECTIVE

Date
May 7, 2023
Explore related products in the following collection:

Society: AGA

Increasing risk for early onset CRC under age 50 has been well established. More recent trends suggest that this risk is extending beyond age 50, potentially expanding the public health impact of the factors driving increased risk. This symposium will: 1) Review the changing epidemiology of colorectal cancer; 2) Review potential causes from epidemiologic and basic science perspectives; 3) Discuss implications of the changing epidemiology for basic/translational research, as well as clinical research and clinical practice.

Presenter

Speaker Image for Sonia Kupfer
University of Chicago

Tracks

Related Products

Thumbnail for DETERMINANTS OF INVASIVE SIGNET RING CELL CARCINOMA IN HEREDITARY DIFFUSE GASTRIC CANCER
DETERMINANTS OF INVASIVE SIGNET RING CELL CARCINOMA IN HEREDITARY DIFFUSE GASTRIC CANCER
BACKGROUND: Colonic polyposis, which is a risk factor for colorectal cancer (CRC), can be driven by a pathogenic variant in a polyposis gene. However, in many cases germline genetic testing is negative, leaving the cause of the polyposis unknown…
Thumbnail for MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for PANEL DISCUSSION
PANEL DISCUSSION
Increasing risk for early onset CRC under age 50 has been well established. More recent trends suggest that this risk is extending beyond age 50, potentially expanding the public health impact of the factors driving increased risk…